Company intelligence / Profile preview

Clariden Biotechnology Fund

Zurich, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

Clariden Biotechnology Fund was a specialized investment vehicle managed by Clariden Leu, a Swiss private bank. The fund focused on the global biotechnology sector, investing in a diversified portfolio of companies ranging from large-cap biopharma to emerging clinical-stage firms. It aimed to capitalize on scientific innovation and the commercialization of new therapies across various therapeutic areas. Following the merger of Clariden Leu into Credit Suisse in 2012, the fund's management and assets were integrated into Credit Suisse's investment platforms. During its operation, it was recognized as a key European fund for institutional and private investors seeking exposure to life science equities.

Industry: Investors

Beyond the preview

Go deeper on Clariden Biotechnology Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clariden Biotechnology Fund.

Explore the full profile